CDDO-TFEA

CDDO-TFEA (RTA 404; TP-500) is a trifluoroacetamide derivative of CDDO with enhanced ability to cross the blood-brain barrier. CDDO is an Nrf2 activator that inhibits proliferation and induces differentiation and apoptosis in various cancer cells. CDDO-TFEA can enhance Nrf2 expression and signaling in various neurodegenerative disease models, including those mimicking multiple sclerosis, amyotrophic lateral sclerosis, and Huntington's disease. CDDO-TFEA induces apoptosis and blocks colony formation in Ewing's sarcoma and neuroblastoma cell lines with IC50 values ranging from 85-170 nM.

Product Specifications

CAS Number

[932730-52-4]

Product Name Alternative

CDDO-Trifluoethyl amide; RTA 404; TP-500

UNSPSC

12352211

Target

Apoptosis; Keap1-Nrf2

Type

Reference compound

Related Pathways

Apoptosis; NF-κB

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cddo-tfea.html

Purity

99.59

Solubility

DMSO : 8.33 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CC(C)([C@](CC[C@@]([C@@]1(CC[C@]2(CCC(C)(C[C@]2([C@]13[H])[H])C)C(NCC(F)(F)F)=O)C)4C)5[H])C(C(C#N)=C[C@]5(C)C4=CC3=O)=O

Molecular Formula

C33H43F3N2O3

Molecular Weight

572.70

References & Citations

[1]Stack, et al. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington’s disease. Free Radic. Biol. Med. 49 (2), 147-158 (2010) .